Rahul Winayak, Postdoctoral Research Fellow in Kidney Cancer at City of Hope, shared on X:
”RCC variant histologies represent a remarkably diverse group of diseases. An outstanding overview of landmark and ongoing trials in the field by Sumanta K. Pal.
Particularly exciting is STELLAR-304, evaluating zanzalitinib plus nivolumab in the frontline nccRCC setting.”
Other articles about renal oncology on OncoDaily.
